POLIO
MCID: PLM031
MIFTS: 60

Poliomyelitis (POLIO) malady

Categories: Rare diseases, Neuronal diseases, Infectious diseases

Aliases & Classifications for Poliomyelitis

Aliases & Descriptions for Poliomyelitis:

Name: Poliomyelitis 12 50 56 42 14 69
Infantile Paralysis 50 69
Polio 50 52

Characteristics:

Orphanet epidemiological data:

56
poliomyelitis
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Childhood; Age of death: any age;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:4953
ICD10 33 A80 A80.9
ICD9CM 35 045 045.9
MeSH 42 D011051
NCIt 47 C35550
Orphanet 56 ORPHA2912
ICD10 via Orphanet 34 A80.4 A80.2 A80.3 more
MESH via Orphanet 43 D011051
UMLS via Orphanet 70 C0032371
UMLS 69 C0032371

Summaries for Poliomyelitis

NIH Rare Diseases : 50 poliomyelitis is a viral disease that can affect nerves and can lead to partial or full paralysis. it is caused by infection with the poliovirus which can be spread by direct person-to-person contact, by contact with infected mucus or phlegm from the nose or mouth, or by contact with infected feces. there are three basic patterns of polio infection: subclinical infections, nonparalytic, and paralytic.symptoms vary based on the pattern of infection and can range from asymptomatic with subclinical poliomyelitis to partial or full paralysis. treatment is aimed at controlling symptoms while the infection runs its course. since the development of polio vaccine, the incidence of the disease has been greatly reduced.the prognosis depends on the form of the disease (subclinical, nonparalytic, or paralytic) and the site affected. last updated: 12/24/2015

MalaCards based summary : Poliomyelitis, also known as infantile paralysis, is related to hepatitis and tuberculosis, and has symptoms including fever, sore throat and headache. An important gene associated with Poliomyelitis is PVR (Poliovirus Receptor), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Zinc and Zinc sulfate have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, bone and testes, and related phenotypes are hematopoietic system and cellular

Disease Ontology : 12 A viral infectious disease that results_in destruction located in motor neurons, has material basis in Human poliovirus 1, has material basis in Human poliovirus 2, or has material basis in Human poliovirus 3, which are transmitted_by ingestion of food or water contaminated with feces, or transmitted_by direct contact with the oral secretions. The infection has symptom fever, has symptom sore throat, has symptom headache, has symptom vomiting, has symptom fatigue, has symptom neck stiffness, has symptom muscle spasms, and has symptom acute flaccid paralysis.

Wikipedia : 71 Poliomyelitis, often called polio or infantile paralysis, is an infectious disease caused by the... more...

Related Diseases for Poliomyelitis

Diseases related to Poliomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 255)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.3 IFNG IL10 TNF
2 tuberculosis 29.5 IL10 IL4 TNF
3 complex regional pain syndrome 29.3 ICAM1 IFNG IL10 TNF
4 nonparalytic poliomyelitis 12.3
5 paralytic poliomyelitis 12.3
6 poliomyelitis in patients with immunodeficiencies deemed at risk 11.8
7 bulbar polio 11.6
8 postpoliomyelitis syndrome 11.1
9 spastic diplegia 10.8
10 spinal polio 10.8
11 bulbospinal polio 10.8
12 myoglobinuria recurrent 10.3 IFNG IL4
13 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
14 tetanus 10.3
15 diphtheria 10.3
16 stocco dos santos syndrome 10.3 IFNG TNF
17 pertussis 10.2
18 ceroid lipofuscinosis, neuronal, 3 10.2 IL10 IL4
19 multiple vertebral anomalies unusual facies 10.2 IL10 TNF
20 ileocolitis 10.2 ICAM1 IL4
21 autosomal dominant deafness-onychodystrophy syndrome 10.2 IFNG IL4 TNF
22 tubular renal disease-cardiomyopathy syndrome 10.2 IL10 IL4 TNF
23 urethral intrinsic sphincter deficiency 10.2 IFNG IL4 TNF
24 clostridium difficile colitis 10.2 IFNG IL4 TNF
25 lagophthalmos 10.2 IL10 IL4 TNF
26 conidiobolomycosis 10.2 IL10 IL4 TNF
27 vestibule of mouth cancer 10.2 IL10 IL4 TNF
28 red cell phospholipid defect with hemolysis 10.2 IFNG IL4 TNF
29 venezuelan hemorrhagic fever 10.2 ICAM1 IFNG TNF
30 congenital hypothyroidism 10.2 IL10 IL4 TNF
31 gonococcal endophthalmia 10.2 IL10 IL4 TNF
32 strawberry gallbladder 10.2 ICAM1 IFNG TNF
33 nasopharyngitis 10.2 IFNG IL4 TNF
34 status epilepticus 10.2 IFNG IL4 TNF
35 eye carcinoma in situ 10.2 IFNG IL4 TNF
36 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.2 IFNG IL10 TNF
37 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.2 ICAM1 IL10 IL4
38 asymptomatic neurosyphilis 10.2 IFNG IL10 IL4
39 peripheral artery disease 10.2 IL10 IL4 TNF
40 hydrophthalmos 10.2 ICAM1 IFNG IL4
41 plantar wart 10.2 IFNG IL10 TNF
42 parkinson disease 11 10.2 IFNG IL10 TNF
43 cyclosporiasis 10.2 IFNG IL10 TNF
44 retinal ischemia 10.2 ICAM1 IFNG TNF
45 tungiasis 10.2 IFNG IL10 IL4
46 periodontosis 10.2 ICAM1 IFNG TNF
47 senile reticular retinal degeneration 10.2 IFNG IL10 TNF
48 pancreatic signet ring cell adenocarcinoma 10.2 IFNG IL10 TNF
49 persistent mullerian duct syndrome 10.2 ICAM1 IL10 TNF
50 pulpitis 10.2 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Poliomyelitis:



Diseases related to Poliomyelitis

Symptoms & Phenotypes for Poliomyelitis

Symptoms:

12
  • fever
  • sore throat
  • headache
  • vomiting
  • fatigue
  • neck stiffness
  • muscle spasms
  • acute flaccid paralysis

MGI Mouse Phenotypes related to Poliomyelitis:

44 (show all 13)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.18 FCGR3B ICAM1 IFNG IL10 IL4 LEP
2 cellular MP:0005384 10.13 BTK DLG1 ICAM1 IFNG IL10 IL4
3 immune system MP:0005387 10.13 BTK DLG1 FCGR2A FCGR3B ICAM1 IFNG
4 digestive/alimentary MP:0005381 10.11 BTK DLG1 ICAM1 IFNG IL10 IL4
5 homeostasis/metabolism MP:0005376 10.11 LEP TNF BTK DLG1 FCGR3B ICAM1
6 endocrine/exocrine gland MP:0005379 10.04 DLG1 ICAM1 IFNG IL10 IL4 LEP
7 integument MP:0010771 9.95 BTK ICAM1 IFNG IL10 IL4 LEP
8 muscle MP:0005369 9.85 DLG1 ICAM1 IFNG IL10 LEP TNF
9 neoplasm MP:0002006 9.8 LEP TNF BTK ICAM1 IFNG IL10
10 no phenotypic analysis MP:0003012 9.73 IL10 IL4 TNF DLG1 FCGR3B IFNG
11 respiratory system MP:0005388 9.63 DLG1 IFNG IL10 IL4 LEP TNF
12 skeleton MP:0005390 9.56 DLG1 FCGR2A FCGR3B IFNG IL10 IL4
13 vision/eye MP:0005391 9.17 DLG1 ICAM1 IFNG IL10 IL4 LEP

Drugs & Therapeutics for Poliomyelitis

Drugs for Poliomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved Phase 4 7440-66-6 32051 23994
2 Zinc sulfate Approved Phase 4 7733-02-0
3
Edetic Acid Approved, Vet_approved Phase 4,Phase 3,Phase 2 60-00-4, 62-33-9 6049
4
Iron Approved Phase 4,Phase 3,Phase 2 7439-89-6 23925
5
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
6
Ibuprofen Approved Phase 4 15687-27-1 3672
7
Menthol Approved Phase 4 2216-51-5 16666
8
Phenol Approved, Experimental Phase 4 108-95-2 996
9
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
10
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 11103-57-4, 68-26-8 445354
11 Antibodies Phase 4,Phase 2,Phase 3
12 Immunoglobulins Phase 4,Phase 2,Phase 3
13 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
14 Micronutrients Phase 4,Phase 2,Phase 3
15 Trace Elements Phase 4,Phase 2,Phase 3
16 Antioxidants Phase 4,Phase 2,Phase 3
17 Protective Agents Phase 4,Phase 3,Phase 2
18 Retinol palmitate Phase 4,Phase 2,Phase 3
19 Vitamins Phase 4,Phase 2,Phase 3
20 BCG Vaccine Phase 4,Phase 2
21 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
22 Anticoagulants Phase 4,Phase 3,Phase 2
23 Fibrinolytic Agents Phase 4,Phase 3
24 PENTA Phase 4,Phase 3
25 Antidotes Phase 4,Phase 3,Phase 2
26 Calcium, Dietary Phase 4,Phase 3,Phase 2
27 Chelating Agents Phase 4,Phase 3,Phase 2
28 Iron Chelating Agents Phase 4,Phase 3,Phase 2
29 Pentetic Acid Phase 4,Phase 3,Phase 2
30 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2,Phase 1
31 Analgesics Phase 4,Phase 3
32 Analgesics, Non-Narcotic Phase 4,Phase 3
33 Anti-Inflammatory Agents Phase 4,Phase 2
34 Anti-Inflammatory Agents, Non-Steroidal Phase 4
35 Antipyretics Phase 4,Phase 3
36 Antirheumatic Agents Phase 4
37 Cyclooxygenase Inhibitors Phase 4
38 Peripheral Nervous System Agents Phase 4,Phase 3
39 Adjuvants, Immunologic Phase 4,Phase 1,Phase 2
40 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1
41 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
42 Polymyxin B Phase 4
43 Polymyxins Phase 4
44 retinol Nutraceutical Phase 4,Phase 2,Phase 3
45 Acidophilus Nutraceutical Phase 4
46 Zinc Supplement Nutraceutical Phase 4
47
Pyrimethamine Approved, Vet_approved Phase 2, Phase 3,Phase 1 58-14-0 4993
48
Sulfadoxine Approved Phase 2, Phase 3,Phase 1 2447-57-6 17134
49
Aluminum hydroxide Approved Phase 3,Phase 1,Phase 2 21645-51-2
50
Dapsone Approved, Investigational Phase 2, Phase 3 80-08-0 2955

Interventional clinical trials:

(show top 50) (show all 308)
id Name Status NCT ID Phase
1 Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine Unknown status NCT01841671 Phase 4
2 A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China Completed NCT01278433 Phase 4
3 Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine Completed NCT01475539 Phase 4
4 A Study of the Safety of IMOVAX Polio™ in China Completed NCT01244464 Phase 4
5 Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan Completed NCT02005536 Phase 4
6 Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine Completed NCT00514059 Phase 4
7 Polio End-game Strategies - Poliovirus Type 2 Challenge Study Completed NCT02189811 Phase 4
8 Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE Completed NCT01546909 Phase 4
9 Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults Completed NCT01323959 Phase 4
10 Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines Completed NCT01616693 Phase 4
11 Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine Completed NCT01831050 Phase 4
12 Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules Completed NCT02412514 Phase 4
13 Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine Completed NCT02643368 Phase 4
14 Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia Completed NCT01094171 Phase 4
15 Regulatory Post-Marketing Surveillance Study for TETRAXIM™ Completed NCT01437423 Phase 4
16 Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine Completed NCT00635128 Phase 4
17 IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi. Completed NCT01695798 Phase 4
18 IPV Clinical Trial - The Gambia Completed NCT01847872 Phase 4
19 Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines Completed NCT00254917 Phase 4
20 Inactivated Influenza Vaccine Effectiveness in Tropical Africa Completed NCT00893906 Phase 4
21 Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine Completed NCT00304265 Phase 4
22 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
23 Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age Completed NCT01031303 Phase 4
24 Direct and Indirect Protection by Influenza Vaccine Given to Children in India Completed NCT00934245 Phase 4
25 Non-Specific Effects of Standard Titre Measles Vaccination Completed NCT00168662 Phase 4
26 Poliovirus Vaccine Trial in Bangladesh Completed NCT01633216 Phase 4
27 Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants Completed NCT00325156 Phase 4
28 Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children Completed NCT00611559 Phase 4
29 Different Doses of Vitamin A and Childhood Morbidity and Mortality Completed NCT00168584 Phase 4
30 Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Course Completed NCT01457547 Phase 4
31 Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™ Completed NCT01358825 Phase 4
32 Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Completed NCT00753649 Phase 4
33 Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
34 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
35 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
36 Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) Completed NCT01926015 Phase 4
37 Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose Completed NCT00712959 Phase 4
38 Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) Completed NCT01294605 Phase 4
39 Influenza Immunization of Children in India Completed NCT01680679 Phase 4
40 Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ Completed NCT00802867 Phase 4
41 Retrospective Survey of Safety of Fourth Dose Pentacel® in Children Completed NCT00772369 Phase 4
42 Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13® Completed NCT01392378 Phase 4
43 Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants Recruiting NCT03147560 Phase 4
44 Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Recruiting NCT02422264 Phase 4
45 Vaccinating Children After Chemotherapy Recruiting NCT02447718 Phase 4
46 Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Recruiting NCT02853929 Phase 4
47 Trial of Two Strains of BCG Recruiting NCT02447536 Phase 4
48 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Recruiting NCT02408926 Phase 4
49 Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial Recruiting NCT02504203 Phase 4
50 To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan Active, not recruiting NCT01908114 Phase 4

Search NIH Clinical Center for Poliomyelitis

Cochrane evidence based reviews: poliomyelitis

Genetic Tests for Poliomyelitis

Anatomical Context for Poliomyelitis

MalaCards organs/tissues related to Poliomyelitis:

39
Spinal Cord, Bone, Testes, Breast, Brain, Lung

The Foundational Model of Anatomy Ontology organs/tissues related to Poliomyelitis:

18
Motor Neurons

Publications for Poliomyelitis

Articles related to Poliomyelitis:

(show top 50) (show all 952)
id Title Authors Year
1
Vaccine Associated Paralytic Poliomyelitis Unmasking Common Variable Immunodeficiency. ( 28361789 )
2017
2
A case-control study on the association of pulse oral poliomyelitis vaccination and Gianotti-Crosti syndrome. ( 27943306 )
2017
3
Morbidity and mortality following poliomyelitis - a lifelong follow-up. ( 27869331 )
2017
4
Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization. ( 28057194 )
2017
5
Asymmetrical bone loss in a patient with poliomyelitis: an indication for anti-osteoporotic therapy. ( 27252750 )
2016
6
Faster Detection of Poliomyelitis Outbreaks to Support Polio Eradication. ( 26890053 )
2016
7
Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents. ( 26803328 )
2016
8
A cluster of paralytic poliomyelitis cases due to transmission of slightly diverged Sabin-2 vaccine virus. ( 27099315 )
2016
9
Effective case/infection ratio of poliomyelitis in vaccinated populations. ( 26830060 )
2016
10
Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2015. ( 27086368 )
2016
11
A Transgenic Mouse Model of Poliomyelitis. ( 26983733 )
2016
12
Shoulder arthroplasty for sequelae of poliomyelitis. ( 26700552 )
2016
13
International Health Regulations in practice: Focus on yellow fever and poliomyelitis. ( 27541082 )
2016
14
Poliomyelitis: residual hurdles to global eradication. Commentary. ( 27999213 )
2016
15
Differential preference for pertussis and poliomyelitis vaccines in urban versus rural parents in Guatemala. ( 27095889 )
2016
16
Outcomes of Total Knee Arthroplasty in Patients With Poliomyelitis. ( 27259390 )
2016
17
Franklin Delano Roosevelt: The Diagnosis of Poliomyelitis Revisited. ( 27178375 )
2016
18
Progress Toward Poliomyelitis Eradication - Afghanistan, January 2015a89August 2016. ( 27811838 )
2016
19
Eradication and Current Status of Poliomyelitis in Pakistan: Ground Realities. ( 27517055 )
2016
20
Comparison and Contrast of the Elimination Campaigns for Poliomyelitis and Leprosy: Which is More Feasible? ( 27349781 )
2016
21
Surveillance of poliomyelitis in Northern Italy: Results of acute flaccid paralysis surveillance and environmental surveillance, 2012-2015. ( 27929744 )
2016
22
Pakistan as a major obstacle in global end to poliomyelitis program: background and 2016 update. ( 27527564 )
2016
23
Intrathecal Analgesic Drug Delivery is Effective for Analgesia in a Patient with Post-Poliomyelitis Syndrome: A Case Report. ( 27980323 )
2016
24
Poliomyelitis in Ancient Egypt? ( 27665570 )
2016
25
Placental antibody transfer efficiency and maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III and HIV-1 antibodies. ( 27934956 )
2016
26
The effect of footwear adapted with a multi-curved rocker sole in conjunction with knee-ankle-foot orthoses on walking in poliomyelitis subjects: a pilot study. ( 27982715 )
2016
27
Acute poliomyelitis. By F. E. Batten MD Cantab FRCP Lond. The Lumleian Lectures for 1916 delivered before the Royal College of Physicians. Brain 1916; 39: 115-211. ( 27086871 )
2016
28
Nucleotide variation in Sabin type 3 poliovirus from an Albanian infant with agammaglobulinemia and vaccine associated poliomyelitis. ( 27287521 )
2016
29
A human quadrupedal gait following poliomyelitis: From the Dercum-Muybridge collaboration (1885). ( 26928358 )
2016
30
Long-term socio-economic consequences and health care costs of poliomyelitis: a historical cohort study involving 3606 polio patients. ( 27083562 )
2016
31
Progress Toward Poliomyelitis Eradication - Pakistan, January 2015-September 2016. ( 27880752 )
2016
32
W. Ritchie Russell, A.B. Baker, and Fred Plum: Pioneers of ventilatory management in poliomyelitis. ( 27621379 )
2016
33
Therapeutic Experience on Stance Control Knee-Ankle-Foot Orthosis With Electromagnetically Controlled Knee Joint System in Poliomyelitis. ( 27152288 )
2016
34
Fixator-assisted tibial lengthening over a plate in a patient with sequelae of poliomyelitis. ( 27858886 )
2016
35
Comprehensive review of challenges associated with management of lower limb fractures in poliomyelitis patients. ( 27857503 )
2016
36
Outcome after cementless total hip arthroplasty for arthritic hip in patients with residual poliomyelitis: a case series. ( 27229169 )
2016
37
Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data. ( 27701425 )
2016
38
Long-term Outcome of Unconstrained Primary Total Hip Arthroplasty in Ipsilateral Residual Poliomyelitis. ( 27841928 )
2016
39
Winning the battle against the scourge of poliomyelitis in the African Region. ( 27576072 )
2016
40
Progress towards poliomyelitis eradication: Pakistan, January 2015a89September 2016. ( 27921417 )
2016
41
556 Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2016. ( 27922012 )
2016
42
Quadracel: Vaccination Against Diphtheria, Tetanus, Pertussis, and Poliomyelitis in Children. ( 27069343 )
2016
43
Total Hip Arthroplasty for the Paralytic and Non-paralytic Side in Patient with Residual Poliomyelitis. ( 27347238 )
2016
44
Performance of acute flaccid paralysis (AFP) surveillance and incidence of poliomyelitis, 2016. ( 27623615 )
2016
45
Experiences of attitudes in Sierra Leone from the perspective of people with poliomyelitis and amputations using orthotics and prosthetics. ( 27829289 )
2016
46
Outcomes of total hip replacement in limbs affected by poliomyelitis. ( 27886358 )
2016
47
Progress towards poliomyelitis eradication: Afghanistan, January 2015a89August 2016. ( 27811982 )
2016
48
Progress Toward Poliomyelitis Eradication--Pakistan, January 2014-September 2015. ( 26584026 )
2015
49
Progress towards poliomyelitis eradication: Pakistan, January 2014a89September 2015. ( 26591026 )
2015
50
Progress towards poliomyelitis eradication in Nigeria, January 2014- July 2015. ( 26298883 )
2015

Variations for Poliomyelitis

Expression for Poliomyelitis

Search GEO for disease gene expression data for Poliomyelitis.

Pathways for Poliomyelitis

Pathways related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 44)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 BTK FCGR2A FCGR3A FCGR3B ICAM1 IFNG
2
Show member pathways
12.77 ICAM1 IFNG IL10 IL4 TNF
3
Show member pathways
12.55 BTK IFNG IL10 IL4 TNF
4
Show member pathways
12.51 IFNG IL10 IL4 TNF
5 12.47 BTK IFNG IL10 IL4 PVR TNF
6
Show member pathways
12.43 FCGR3A FCGR3B ICAM1 IFNG IL4 TNF
7
Show member pathways
12.36 DLG1 IFNG IL10 IL4 TNF
8
Show member pathways
12.26 ICAM1 IFNG IL4 TNF
9
Show member pathways
12.15 IFNG IL10 IL4 LEP
10 12.1 FCGR2A FCGR3A FCGR3B IFNG IL10 TNF
11
Show member pathways
12.09 IFNG IL10 IL4 TNF
12
Show member pathways
12.08 IFNG IL4 TNF
13 12.05 FCGR2A FCGR3A FCGR3B
14 12 ICAM1 IFNG TNF
15 11.99 FCGR3A ICAM1 PVR
16
Show member pathways
11.97 BTK FCGR2A FCGR3B
17 11.92 ICAM1 IL10 IL4 TNF
18 11.9 FCGR2A IFNG IL10 IL4 TNF
19
Show member pathways
11.87 IFNG IL10 TNF
20 11.84 BTK FCGR2A FCGR3A FCGR3B IFNG TNF
21 11.82 IFNG IL10 TNF
22 11.81 BTK ICAM1 TNF
23 11.79 ICAM1 IFNG TNF
24
Show member pathways
11.77 FCGR2A FCGR3A FCGR3B IFNG IL10 IL4
25 11.74 ICAM1 IFNG IL4
26 11.74 IFNG IL10 IL4 TNF
27 11.71 FCGR2A ICAM1 IFNG IL4 LEP TNF
28
Show member pathways
11.7 IFNG IL4 TNF
29 11.7 IFNG IL10 TNF
30
Show member pathways
11.61 ICAM1 IFNG TNF
31 11.52 ICAM1 IL10 IL4 TNF
32 11.5 ICAM1 IFNG IL10 TNF
33 11.47 IFNG IL10 IL4
34 11.47 FCGR2A FCGR3A FCGR3B ICAM1 IL10
35
Show member pathways
11.38 IFNG IL10 TNF
36 11.3 ICAM1 IFNG IL10 TNF
37 11.27 IFNG IL4 TNF
38 11.18 IFNG IL10 IL4 TNF
39 11.16 IFNG IL10 IL4
40 11.15 BTK IL10 IL4 TNF
41 11.09 ICAM1 IFNG
42 11.03 LEP TNF
43 11.01 FCGR2A FCGR3A FCGR3B ICAM1 IL10 IL4
44 10.88 ICAM1 TNF

GO Terms for Poliomyelitis

Cellular components related to Poliomyelitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 FCGR3B IFNG IL10 IL4 LEP PVR
2 extracellular space GO:0005615 9.5 ICAM1 IFNG IL10 IL4 LEP PVR
3 membrane raft GO:0045121 9.46 BTK DLG1 ICAM1 TNF
4 external side of plasma membrane GO:0009897 9.02 FCGR3A ICAM1 IFNG IL4 TNF

Biological processes related to Poliomyelitis according to GeneCards Suite gene sharing:

(show all 41)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.93 ICAM1 IFNG IL10 IL4
2 positive regulation of protein phosphorylation GO:0001934 9.85 IFNG IL4 TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 BTK ICAM1 TNF
4 response to ethanol GO:0045471 9.83 ICAM1 IL4 LEP
5 single organismal cell-cell adhesion GO:0016337 9.83 DLG1 ICAM1 PVR
6 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051091 9.82 IL10 IL4 TNF
7 response to organic substance GO:0010033 9.8 BTK IL10 TNF
8 immune response GO:0006955 9.8 FCGR3A FCGR3B IFNG IL10 IL4 TNF
9 response to insulin GO:0032868 9.77 ICAM1 IL10 LEP
10 regulation of insulin secretion GO:0050796 9.77 IFNG LEP TNF
11 positive regulation of T cell proliferation GO:0042102 9.76 IFNG IL4 LEP
12 cellular response to lipopolysaccharide GO:0071222 9.76 ICAM1 IFNG IL10 TNF
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.71 ICAM1 IFNG TNF
14 positive regulation of protein complex assembly GO:0031334 9.68 IFNG TNF
15 cortical actin cytoskeleton organization GO:0030866 9.68 DLG1 TNF
16 positive regulation of osteoclast differentiation GO:0045672 9.68 IFNG TNF
17 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.67 IL10 TNF
18 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.67 IFNG TNF
19 negative regulation of B cell proliferation GO:0030889 9.66 BTK IL10
20 leukocyte tethering or rolling GO:0050901 9.65 LEP TNF
21 negative regulation of nitric oxide biosynthetic process GO:0045019 9.65 IL10 IL4
22 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.64 IL10 TNF
23 negative regulation of glucose import GO:0046325 9.63 LEP TNF
24 positive regulation of isotype switching to IgG isotypes GO:0048304 9.62 IFNG IL4
25 negative regulation of lipid storage GO:0010888 9.61 LEP TNF
26 endothelial cell apoptotic process GO:0072577 9.61 IL10 TNF
27 negative regulation of endothelial cell apoptotic process GO:2000352 9.61 ICAM1 IL10 IL4
28 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 IL10 TNF
29 negative regulation of mitotic cell cycle GO:0045930 9.58 DLG1 IL10 TNF
30 type 2 immune response GO:0042092 9.57 IL10 IL4
31 regulation of isotype switching GO:0045191 9.56 IL10 IL4
32 positive regulation of mononuclear cell migration GO:0071677 9.55 IL4 TNF
33 regulation of immune response GO:0050776 9.55 FCGR3A ICAM1 IFNG IL4 PVR
34 defense response to protozoan GO:0042832 9.54 IFNG IL10 IL4
35 receptor biosynthetic process GO:0032800 9.52 IL10 TNF
36 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.51 ICAM1 TNF
37 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
38 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 IFNG TNF
39 negative regulation of growth of symbiont in host GO:0044130 9.43 IFNG IL10 TNF
40 positive regulation of chemokine biosynthetic process GO:0045080 9.13 IFNG IL4 TNF
41 positive regulation of MHC class II biosynthetic process GO:0045348 8.8 IFNG IL10 IL4

Molecular functions related to Poliomyelitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.33 IL10 IL4 LEP
2 cytokine activity GO:0005125 9.26 IFNG IL10 IL4 TNF
3 IgG binding GO:0019864 8.8 FCGR2A FCGR3A FCGR3B

Sources for Poliomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....